Pembrolizumab, Olaparib, Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer With HRR Mutation and MSS

Gastric Cancer Stage IV Clinical Trial

Official title:
An Open Label, Single-Arm, Multi-center Phase Ib/II Study to Evaluate the Efficacy of Paclitaxel in Combination With Pembrolizumab and Olaparib as a Second Line Treatment in Recurrent/Advanced Gastric and Gastro-esophageal Junction(GEJ) Cancer With Homologous Recombination Repair (HRR) Mutation and Microsatellite Stable (MSS).

Status Not yet recruiting

Clinical Trial Summary

Pembrolizumab is a potent humanized immunoglobulin G4 (IgG4) monoclonal antibody (mAb) with high specificity of binding to the programmed cell death 1 (PD 1) receptor, thus inhibiting its interaction with programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). Olaparib is a potent PARP inhibitor (PARP1, 2, and 3) that is being developed as a monotherapy as well as for combination with chemotherapy, ionizing radiation, and other anti-cancer agents including novel agents and immunotherapy. Paclitaxel is widely used in breast, lung and gastric cancer with every 3-week or weekly cycle. Various targeted anticancer agents have been investigated with paclitaxel and combination with ramucirumab, a monoclonal anti-VEGFR2 antibody, was approved as a 2nd line treatment.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04592211
Study type	Interventional
Source	Yonsei University
Contact	Sun Young Rha, MD. Ph.D
Phone	82-2-2228-8053
Email	rha7655@yuhs.ac
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	October 1, 2021
Completion date	May 31, 2023

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05301465` - Predictive Role of Circulating Angiogenic Factors for Second-line Paclitaxel and Ramucirumab.
Active, not recruiting	`NCT06034964` - Tislelizumab Combined With Chemotherapy in First-line Treatment of AGC
Recruiting	`NCT05204173` - Efficacy and Safety of Sintilimab Combined Intraperitoneal and Intravenous Paclitaxel Plus Oral S-1 in Gastric Cancer Patients With Peritoneal Metastasis	Phase 2
Active, not recruiting	`NCT04267549` - Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer	Phase 2
Recruiting	`NCT06342427` - Stomach Cancer Exosome-based Detection
Recruiting	`NCT04563975` - Efficacy and Safety of Toripalimab Combined With Docetaxel or Nab-paclitaxel in Patients With Advanced Gastric Cancer	Phase 2
Terminated	`NCT04168931` - Trastuzumab to Patients With Advanced Gastric Cancer With HER2 Positive Expression in CTC	Phase 2
Recruiting	`NCT03701373` - Maintenance Treatment With S-1 in Gastric Cancer Patients	Phase 2
Recruiting	`NCT05319639` - Phase I/II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab	Phase 1/Phase 2
Completed	`NCT03618758` - Intraperitoneal Paclitaxel Plus Systemic mFOLFOX6	Phase 1/Phase 2
Completed	`NCT03755440` - PD-1 Antibody in EBV Positive Metastatic Gastric Cancer Patients.	Phase 2
Completed	`NCT03159585` - To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors	Phase 1